Hydrocortisone (Oral Replacement)
Brand names: Plenadren (modified release), Efmody (dual-release), hydrocortisone (standard)
Oral hydrocortisone used as physiological glucocorticoid replacement in adrenal insufficiency, including Addison's disease, secondary adrenal insufficiency, and congenital adrenal hyperplasia.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Hydrocortisone is synthetic cortisol that binds glucocorticoid receptors to replace deficient endogenous cortisol, restoring metabolic, cardiovascular, and stress-response function, typically dosed to mimic the circadian rhythm.
Prescribing in practice
- The most important safety point is the risk of life-threatening adrenal crisis if doses are missed or not increased during illness; patients require sick-day dosing rules, an emergency injection kit, and a steroid emergency card.
- Replacement must not be stopped abruptly, and doses are increased to provide stress cover for intercurrent illness, surgery, or trauma.
- Concurrent enzyme-inducing drugs can increase cortisol clearance and may necessitate dose adjustment.
Monitoring
Monitor clinically for adequacy of replacement and for signs of over- or under-treatment, including blood pressure, weight, and well-being rather than routine cortisol levels.
Counselling the patient
- Never stop your steroid suddenly, and always carry your steroid emergency card.
- Double your dose during fever or illness and know how to use your emergency injection if vomiting prevents tablets.
- Seek urgent medical care if you cannot keep tablets down or feel severely unwell.
Evidence & guidelines
Glucocorticoid replacement with hydrocortisone is standard in adrenal insufficiency, and the MHRA and NHS have issued steroid emergency card guidance to reduce adrenal crisis.
Reference: Society for Endocrinology Addison's guidelines; BSPED CAH guidelines; Arlt et al Lancet 2003; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Modified Mallampati Classification · Airway Assessment
- Modified Early Warning Score (MEWS) · Early Warning
- Modified Shock Index (MSI) · Haemodynamic Assessment
- Modified Sgarbossa's Criteria (Smith Modification) for MI in LBBB · ECG Interpretation
- DAPT Score · Coronary Artery Disease
- PRECISE-DAPT Score for Bleeding on DAPT · Coronary Artery Disease
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016